Brokerages Expect ChromaDex Co. (NASDAQ:CDXC) Will Post Earnings of -$0.09 Per Share

Equities research analysts expect ChromaDex Co. (NASDAQ:CDXCGet Rating) to report ($0.09) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for ChromaDex’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.12). ChromaDex posted earnings of ($0.12) per share during the same quarter last year, which would indicate a positive year over year growth rate of 25%. The firm is scheduled to issue its next earnings results after the market closes on Monday, January 1st.

On average, analysts expect that ChromaDex will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.40) to ($0.12). For the next financial year, analysts anticipate that the business will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.34) to ($0.06). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for ChromaDex.

ChromaDex (NASDAQ:CDXCGet Rating) last released its earnings results on Wednesday, March 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. The firm had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $18.42 million. ChromaDex had a negative return on equity of 70.85% and a negative net margin of 40.22%. During the same quarter in the previous year, the business posted ($0.10) EPS.

CDXC has been the topic of a number of analyst reports. B. Riley dropped their price objective on ChromaDex from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 10th. StockNews.com initiated coverage on ChromaDex in a research note on Thursday, March 31st. They set a “hold” rating on the stock. HC Wainwright dropped their price objective on ChromaDex from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, April 18th. Roth Capital initiated coverage on ChromaDex in a research note on Tuesday, March 8th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research cut ChromaDex from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $7.56.

In other ChromaDex news, CEO Robert N. Fried bought 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 16th. The shares were acquired at an average cost of $2.16 per share, with a total value of $54,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.84% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Merriman Wealth Management LLC acquired a new position in ChromaDex in the 1st quarter valued at $29,000. Citigroup Inc. grew its holdings in ChromaDex by 66.8% in the 3rd quarter. Citigroup Inc. now owns 5,339 shares of the company’s stock valued at $33,000 after buying an additional 2,139 shares in the last quarter. Royal Bank of Canada grew its holdings in ChromaDex by 70.8% in the 3rd quarter. Royal Bank of Canada now owns 5,482 shares of the company’s stock valued at $35,000 after buying an additional 2,273 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in ChromaDex in the 4th quarter valued at $38,000. Finally, ProShare Advisors LLC acquired a new position in ChromaDex in the 4th quarter valued at $38,000. 29.64% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ CDXC opened at $1.64 on Friday. The stock has a market capitalization of $112.07 million, a price-to-earnings ratio of -4.00 and a beta of 1.79. The stock’s 50 day moving average price is $2.22 and its two-hundred day moving average price is $3.39. ChromaDex has a 52 week low of $1.52 and a 52 week high of $10.78.

About ChromaDex (Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Further Reading

Get a free copy of the Zacks research report on ChromaDex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.